R&D The Autumn Budget: What it means for UK life sciences deVere and Inventus comment on the UK Autumn Budget and what it means for life sciences in the country.
Market Access Money vs mindset: How the NHS can make the most of extra inv... It was the day we’d all been waiting for. Rachel Reeves’ Autumn Budget felt like it had been on the horizon for a while.
News NHS under scrutiny amid worst-ever performance in cancer and... The performance of the NHS has come under the spotlight once again, following figures showing worst-ever performances against waiting times targets for cancer treatment and in A&E.
News Tax breaks could nurture UK’s cell and gene therapy manufact... Tax breaks for R&D and innovative manufacturing could be part of life sciences strategy.
News NHS set to lose out to Brexit in budget Brexit bill and debt levels make spending spree unlikely, says Chancellor
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
